Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 11, 1997

View Archived Issues

Takeda reports MIP-1alpha/RANTES receptor antagonists

New hydroxamic acid compounds inhibiting TNF, PDE IV and/or MMPs

SKB patents several series of vitronectin receptor antagonists

New opioid analgesics from Astra

New atypical antipsychotic agent from HMR

YM-60828: an orally active factor Xa inhibitor from Yamanouchi

Novartis launches Exelon

Topical foscarnet for treatment of herpes labialis

MiniMed and LRX combine forces for pulmonary hypertension treatment

AMO Array Multifocal IOL approved for marketing in U.S.

PharmaPrint begins phase II trial of herbal treatment for BPH

Lark signs DNA sequencing agreement with ZymoGenetics

Expanded uses of LifeCell's AlloDerm discussed at recent meeting

Geron awarded SBIR grant for development of telomerase-based diagnostics

IDEC licenses rights to novel antiinflammatory technology

Promising initial results reported for VasoCare therapy in Raynaud's disease

Final phase I/IIa data reported on oral Panretin in APL

Oxygent enhances oxygenation more effectively than blood in surgical patients

Meridian's rapid test for rotavirus approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...